The multiplex real-time PCR assay enables the simultaneous detection of Trichomonas vaginalis or Mycoplasma genitalium in urine and vaginal samples.
Aiming to receive 501(k) clearance for its M. genitalium detection panel early next year, the firm plans to initially target the assay for use in US hospitals and private pathology centers.
The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.
The firm's product revenues were up 19 percent year over year, while license and royalty revenues, as well as R&D, milestone, and grant revenues increased sharply.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The ResistancePlus MG Positive Control kit was listed with the FDA for sale in the US, where it will be sold through SpeeDx's US entity.
LetsGetChecked's platform allows patients to order physician-approved lab tests, and then send their samples to the company for analysis and test results.
The company narrowed its net loss for Q4 2017 to $2.0 million, or $.16 per share, compared to a net loss of $2.6 million, or $.21 per share, in Q4 2016.
The Artus T. vaginalis QS-RGQ kit is designed for the qualitative detection of Trichomonas vaginalis DNA purified from clinician-collected patient samples.